

*The information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation*

2 February 2026

**Beacon Rise Holdings Plc**  
**("Beacon Rise" or the "Company")**

**Update in relation to the Proposed Cowes Chiropractic Acquisition**

On 4 November 2025 Beacon Rise (LSE: BRS) announced that it had entered non-binding heads of terms save for exclusivity, due diligence costs and other customary terms in relation to the proposed acquisition of the entire issued and to be issued share capital of Lyfe Health Isle of Wight Limited ("**Lyfe Health**") (trading as Cowes Chiropractic) by the Company for a consideration of approximately £0.5 million (the "**Proposed Cowes Chiropractic Acquisition**").

Following the review of commercial and financial due diligence materials in connection with the Proposed Cowes Chiropractic Acquisition, the board of directors of Beacon Rise (the "**Board**" or the "**Directors**") have concluded that it would not be in the best interest of the Company's shareholders to pursue the Proposed Cowes Chiropractic Acquisition. Accordingly, the Board has terminated discussions in relation to the Proposed Cowes Chiropractic Acquisition with immediate effect.

The Company continues to progress due diligence in relation to the three other previously announced proposed acquisitions.

**Temporary suspension of listing and trading of Ordinary Shares**

The Proposed Ergotec Acquisition, the Proposed Chiropractor Acquisition and the Proposed Training-provider Acquisition (together the "**Proposed Acquisitions**") are respectively classified as an "initial transaction" under UK Listing Rules ("**UKLR**") 13.4. In accordance with UKLR 21.1.4 and 21.3, the Company ordinary shares of £1.00 each (ISIN: GB00BMC0V753) will remain suspended from its listing on the equity shares (shell companies) category of the Official List of the FCA and from trading on the Main Market of the London Stock Exchange.

Should final terms for any of the proposed acquisitions be agreed, the Company will issue an announcement with further details pursuant to UKLR 13.4.22R and UKLR 13.4.23R.

There can be no certainty that the Proposed Acquisitions will successfully complete, nor as to the final terms or timing of the Proposed Acquisitions. If the Proposed Acquisitions do not complete for any reason, it is expected that the suspension of the Company's listing on the Official List will be lifted, subject to FCA approval, and trading in the Company's shares on the Main Market of the London Stock Exchange will recommence.

Furthermore, it remains the case that each of the proposed acquisitions are separate and not inter-conditional. Accordingly, each of the proposed acquisitions will not be impacted by either failing to complete for any reason.

The Company will seek to simultaneously enter into final binding acquisition agreements in respect of the Proposed Acquisitions prior to Cancellation and Admission. However, the Company intends to proceed with Cancellation and Admission should a final binding acquisition agreement be agreed in relation to at least one of the proposed acquisitions.

The Company will release further announcements as and when appropriate.

**Unless otherwise defined, definitions contained in this announcement have the same meaning as set out in the Company's notification on 29 September 2025 at 8:11 a.m.**

**Enquiries:**

**Beacon Rise Holdings Plc**  
Xiaobing Wang, Chief Executive Officer & Director

[info@beaconrise.uk](mailto:info@beaconrise.uk)

**Allenby Capital Limited** - Sponsor and Financial Adviser  
John Depasquale / Vivek Bhardwaj / Ashur Joseph

Tel: +44 (0)20 3328 5656  
[info@allenbycapital.com](mailto:info@allenbycapital.com)

**LDC Nominee Secretary Limited** - Company Secretary

[beaconriseccs@lawdeb.com](mailto:beaconriseccs@lawdeb.com)

**Legal Entity Identifier (LEI)**

2138007PIYMZMBWD4M27

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACQBUGDDSGGDGLD